Update to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV

Cross-posted from: ClinicalInfo

The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV have been updated.

Immunizations for Preventable Diseases in Adults and Adolescents With HIV

• Adjusted the respiratory syncytial virus (RSV) vaccine guidance to reflect an expanded age range (50–74 years) for people with comorbid conditions and updated the recommendation rating.
• Updated the evidence summaries for herpes zoster, measles, varicella zoster, and COVID-19 vaccines; noted that people with advanced HIV may receive an additional dose of COVID-19 vaccine 6 months after their last dose.

Varicella-Zoster Virus Disease

• Updated the guidance for varicella post-exposure prophylaxis and treatment options for ocular manifestations of varicella-zoster virus disease.
• Updated the recommended period at which the varicella vaccine can be administered to people who have received antiviral post-exposure prophylaxis from >72 hours to >24 hours.

These guidelines are published in an electronic format and updated as changes occur in prevention and treatment science. All updates are developed by the subject matter groups listed in Appendix B and reviewed by scientific content experts.

To view or download the guidelines, go to the Adult and Adolescent Opportunistic Infection Guidelines section of the Clinicalinfo website. The guidelines tables and recommendations also can be downloaded as separate PDF files.

Clinicalinfo welcomes your feedback on the latest revisions to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. Please send your comments with the subject line “Adult and Adolescent Opportunistic Infection Guidelines” to HIVinfo@NIH.gov by March 18.